BTLA and neoplasm: To verify our guess, we investigated tumor-related immune checkpoints, including CD273, CD274, CTLA-4, and the ones that were newly emerging, LAG-3, TIM-3, TIGIT, CD276, BTLA, and IDO1 [26], between the two subgroups.